Applied Genetic Technologies Corporation has completed enrollment in the third group of a dose escalation portion of a phase 1/2 trial of its subretinal injection achromatopsia treatment candidate, according to a press release.
AGTC is evaluating the safety and efficacy of rAAV2tYF-PR1.7-hCNGA3 in patients with achromatopsia (ACHM) caused by mutations in the CNGA3 gene. A parallel phase 1/2 trial is evaluating the company’s product candidates in ACHM caused by mutations in the CNGB3 gene.
“This achievement is another demonstration of our continued progress in the clinical
Uncategorized